Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC)

Prior treatment

• Participants with known brain metastases, except those meeting the following criteria: Brain metastases that have been treated locally and are clinically stable for at least 4 weeks prior to the start of treatment; No ongoing neurological symptoms that are related to the brain localization of the disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable).
• Cerebrovascular accident/stroke (< 6 months prior to enrollment).

Other illness

• Participant has a history of malignancy within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hypertropia, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor’s Medical Monitor, is considered cured with minimal risk of recurrence within 3 years).
• Participants with active chronic inflammatory bowel disease (e.g., ulcerative colitis, Crohn’s disease, intestinal perforation) and/or bowel obstruction.

Lab values

• Cardiac arrhythmia, unstable angina, myocardial infarction, congestive heart failure (New York Heart Association [NYHA] ≥ II) or a coronary revascularization procedure within 180 days of study entry. Calculated QTc average (using the Fridericia correction calculation) of > 470 milliseconds (ms).

Other

• Participants with diarrhea (liquid stool) or ileus Grade > 1.

• Participants are capable of signing informed consent as defined in protocol.
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤1.
• Participants with adequate hematologic, hepatic and renal function as defined in protocol.
• Participant must have at least 1 lesion that is measurable using RECIST v1.1.
• Participants with histologically or cytologically confirmed advanced or metastatic PDAC, who were intolerant/refractory to or progressed after systemic therapies for the advanced metastatic stage.
• Participants must have received and progressed (according to RECIST v1.1) on at least one 1 line of therapy for the treatment of advanced/metastatic disease but no more than 2.
• All participants will be screened using an IHC test to define CEACAM5 expression. Only participants with CEACAM5 high expressing tumors will be eligible.